Excessive free radical formation and depletion of the brain's primary antioxidant,
glutathione, are established components of Parkinson's disease (PD) pathophysiology. While
there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some
preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles
surrounding currently employed delivery methods have hindered the clinical utility of this
therapy. Intranasal GSH, (in)GSH, is a novel method of glutathione augmentation. The aim of
this study is to evaluate whether 200 mg of (in)GSH results in measurable changes in brain
glutathione concentrations, as measured by magnetic resonance spectroscopy (MRS) in 15
individuals with PD.
Phase:
Phase 1
Details
Lead Sponsor:
University of Washington
Collaborator:
Michael J. Fox Foundation for Parkinson's Research